Stemirac injection, a regenerative medicine drug for spinal cord injuries jointly developed by Sapporo Medical University and Nipro, has taken a step toward formal approval. Reports indicate that efforts are under way to obtain the world’s first approval.
Stemirac injection, jointly developed by Sapporo Medical University and Nipro, is being developed as a regenerative medicine drug for spinal cord injuries. Reports indicate that efforts are under way to obtain formal approval in Japan.
Nipro has filed a second application as part of the drug’s approval process, and the application is reportedly a step toward formal approval. Developments in a clinical trial concerning expansion of its indications to ALS have also been cited as related information.